Metallothionein Levels in Ovarian Tumours Before and After Chemotherapy
Author Information
Author(s): D. Murphy, A.T. McGown, D. Crowther, A. Mander, B.W. Fox
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital
Hypothesis
Does metallothionein content influence tumour sensitivity in ovarian cancer?
Conclusion
Ovarian tumours have significantly higher metallothionein levels than normal ovaries, but chemotherapy does not change these levels.
Supporting Evidence
- Ovarian tumours have over 100-fold higher metallothionein levels compared to normal ovaries.
- Chemotherapy does not significantly change metallothionein levels in ovarian tumours.
- Metallothionein levels were not related to clinical response, tumour size, histology, differentiation state, or age.
Takeaway
Ovarian cancer tumours have a lot more metallothionein than normal ovaries, but this doesn't help them respond better to chemotherapy.
Methodology
Tumour samples were collected from patients before and after chemotherapy, and metallothionein levels were measured using a specific binding assay.
Limitations
The study does not provide information on tumour heterogeneity or changes in metallothionein levels during therapy.
Participant Demographics
Patients undergoing surgery for ovarian cancer, with a median age of 46 for the control group.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website